About US
Contact us
-
SFDA releases 2011 Annual Report for National Adverse Drug Reaction MonitoringThe State Food and Drug Administration (SFDA) recently released the 2011 Annual Report for National Adverse Drug Reaction Monitoring, which gave information about national ADR reporting of 2011, inclu2012/6/4
-
Icahn plans another foray against Forest LabsForest Laboratories ($FRX) CEO Howard Solomon is having an unwelcome case of déjà vu. Activist investor Carl Icahn plans to come back to the proxy ring with another set of director nominees. Along2012/6/1
-
EMA database of adverse-event reports opens to publicThe European Medicines Agency has opened up access to reports of suspected drug side effects. The now-public database comprises reports on about 650 medications and active ingredients cleared for sale2012/6/1
-
SFDA Commissioner Yin Li meets the delegation of Ministry of Industry, Trade and Labor of IsraelOn May 29, 2012, Yin Li, Commissioner of the State Food and Drug Administration (SFDA) met with the delegation led by Mr. Shalom Simhon, Minister of Industry, Trade and Labor of Israel. Both sides exc2012/5/31
-
Adderall shortage spurs counterfeiters to step in, FDA saysDrug shortages are a conundrum for pharma. They're frustrating, even infuriating, to hospitals and patients. To counterfeiters, they're a promise of new business. For evidence, look no further than2012/5/31
-
Big Pharma sweats outcome of Supreme Court rulingAt 18% of gross domestic product, healthcare spending in the United States is the highest in the world. And if the healthcare reform bill gets shot down by the Supreme Court, pharma will pop into t2012/5/30
-
Teva says no thank you to generic LipitorGenerics makers are preparing to flood the market with copycat Lipitor, now that Ranbaxy Laboratories' exclusivity period is expiring. But Teva Pharmaceutical Industries ($TEVA) won't be joining th2012/5/30
-
EMA supports Pradaxa but seeks sharper warnings for bleedingEuropean regulators say the upside of blockbuster drug Pradaxa still outweighs its the risks of fatal bleeding, but they want some more labeling caveats for the blockbuster drug. The European Medicin2012/5/29
-
House could vote on FDA bill next weekThe Senate Thursday voted 96-1 vote in favor of re-authorization of PDUFA. It now goes to the House, whose own version to extend the user-fee act for another 5 years is similar to the Senate's bill, T2012/5/29
-
SFDA Commissioner Yin Li attends the opening ceremony of the 4th DIA China Annual MeetingOn May 21, 2012, Yin Li, Commissioner of the State Food and Drug Administration (SFDA), attended the opening ceremony of the 4th DIA (Drug Information Association) China Annual Meeting in Shanghai and2012/5/28